1,721,100 research outputs found
Macular sensitivity change in multiple sclerosis followed with microperimetry
No full textPURPOSE. To describe the efficacy of MP-1 in detecting early multiple sclerosis (MS) retinal lesions and in monitoring the effectiveness of treatment in terms of changes in macular sensitivity. METHODS. A 21-year-old woman with MS was referred to us complaining of recurrent episodes of eyesight loss in both eyes. At ophthalmologic examination, best-corrected visual acuity was 20/25 bilaterally; ophthalmoscopy showed bilateral slight optic neuritis without swelling of the disc. Static perimetry of central visual field (30 degrees, by Octopus 101, Haag-Streit AG, Switzerland) and retinal sensitivity of the 12 central degrees (by MP-1 Micro Perimeter, Nidek Inc., Italy) were performed on the patient at that time. The microperimeter (MP-1) showed a loss of sensitivity in the macular region with 0.28 +/- 0.9 dB sensitivity in the right eye and 19.42 +/- 1.5 dB in the left. The mean fixation stability was 91 % considering 20 and 99% considering 4 degrees around the fixation points in the right eye, and 97% in 2 degrees and 100% in 4 degrees central degrees in the left. In the weeks that followed vision continued to get worse in both eyes, so she underwent a steroid therapy with methylprednisolone IV 1000 mg/day for 5 days and 500 mg/day for 3 days. RESULTS. After 8 days of therapy the MP-1 showed a significant recovery in the right eye, with mean light sensitivity being 19.61 +/- 1.3 dB in the right eye and 20.0 +/- 0 dB in the left eye in both macular and peripapillary regions. The mean fixation stability was 100% considering 2 degrees and 100% considering 4 degrees around the fixation points in both eyes. CONLCUSIONs. The MP-1 can be an interesting tool for neuro-ophthalmologists as it allows a more precise evaluation of the macular and peripapillary region, which is not easily studied with conventional automated perimetry. In MS, the presence of a subclinical form of optic nerve involvement can be demonstrated in a very early stage, and well followed by the introduction of microperimeter testing in the standard examination protocol
Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments.
No full textThe aim of the study is to evaluate the effectiveness and safety of intravitreal infliximab in the course of compassionate use in patients affected by choroidal neovascularization. This prospective interventional case series includes four eligible patients, affected by exudative age-related macular degeneration (2/4), retinal angiomatous proliferation (1/4) and central retinal vein occlusion (1/4), who were refractory to conventional treatments. The patients received a single intravitreal injection of 0.05 ml of reconstituted infliximab solution (20mg/ml). The main outcomes measure were changes in best-corrected visual acuity and central retinal thickness. Patients were evaluated at baseline, every week for the first month, then every two weeks, and on demand. Morphologic parameters improved after a single infliximab intravitreal injection. However, all patients developed acute uveitis in a period ranging from 4 to 7 weeks after treatment. Control of the intraocular inflammation was achieved with topical and systemic steroids in 3 patients, whereas in one case pars plana vitrectomy was needed. A single intravitreal injection of infliximab does not seem to improve the natural history of CNV from different aetiologies. However, all patients in our series developed a serious inflammatory response that required surgical management in one case. The intravitreal administration of infliximab is hence not safe and not recommended in clinical practice
Corrigendum - Intraocular pressure changes following the use of silicone oil or Densiron 68 as endotamponade in pars plana vitrectomy
No full textRomano MR, Angi M, Romano V, et alA word was omitted from the conclusion of the Abstract. The correct version is as follows:Conclusion: Overall, the use of Densiron 68 was not associated with significantly higher IOP values as compared with SSO
Bilateral Keratectasia 34 Years after Corneal Transplant
No full textWe report the clinical findings of a patient with severe bilateral keratectasia 34 years after a penetrating keratoplasty (PK) in both eyes. An otherwise healthy 67-year-old man complained of deterioration of the eyesight in both eyes over the last 6 months. The patient was diagnosed with bilateral keratoconus at the age of 32 years, and he underwent a bilateral PK. At presentation, visual acuity was 20/200 in the right eye and light perception in the left eye. A Pentacam pachymetric map revealed a central pachymetry of 720 µm in the right eye and of 710 µm in the left eye, as well as an average paracentral pachymetry of 436 and 270 µm in the 9-mm zone in the right and the left eye, respectively. Corneal topography revealed bilateral irregular and asymmetric bowing with generalized steepening and high corneal power. We describe a case of bilateral keratectasia 34 years after PK in a patient who was originally diagnosed with bilateral keratoconus
Dispositivo per determinare la citotossicità di sostanze applicabili su tessuti epiteliali, procedimento per preparare il dispositivo e metodo per determinare detta tossicità mediante l'uso del dispositivo (B2A-P test).
No full textMacular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient
No full text
Tear histamine assay by fluorescamine derivatization and high performance liquid chromatography.
No full text- …
